Puma Biotechnology, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Puma Biotechnology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 8.4 times. Higher than 94% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$130Over the last 3 years, every $100 of reported profit came with $130 of operating cash.
Lower than 65% of Healthcare companies in United States.
Self-Funding Ratio
8.4×Over the last 3 years its own operating cash covered its investment spending (capex) 8.4 times.
Higher than 94% of Healthcare companies in United States.
Cash Locked Ratio
$24For every $100 of sales, $24 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $18 tied up three years earlier.
More money tied up than 50% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +0% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+0% / -3%In 3 years sales changed by +0% while total assets changed by -3%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
1.9×Debt due within a year is covered 1.9 times by its yearly operating cash.
Higher than 74% of Healthcare companies in United States.
Cash Cushion Ratio
+12%Cash, after subtracting all debt, equals 12% of its market value (net cash).
Higher than 53% of Healthcare companies in United States.
Tangible Assets Ratio
81%Of every $100 the company owns, $81 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 51% of Healthcare companies in United States.
Tangible Net Worth Ratio
68%Of every $100 of net worth, $68 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 55% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Puma Biotechnology, Inc. owes $0.28 for every $1 it owns. Net profit rose 3% in the year to Dec 2025, and grew 2396% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
22.1Investors pay $22.1 for every $1 of Puma Biotechnology, Inc.'s yearly profit, lower than 59% of Healthcare companies in United States.
P/B ratio
4.20The share price is 4.20 times Puma Biotechnology, Inc.'s book value per share, higher than 67% of Healthcare companies in United States.
Market cap
$581 MThe total market value of all of Puma Biotechnology, Inc.'s shares at today's price (share price × number of shares), larger than 57% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$139 MWhat Puma Biotechnology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.68Net worth divided by the number of shares. The share price of $11.26 is 4.2 times this, which is the P/B above.
Return on equity (ROE)
22.0%Puma Biotechnology, Inc. earned 22.0% on its shareholders' money over the last year, higher than 91% of Healthcare companies in United States.
Owes vs Owns
0.28×Puma Biotechnology, Inc. owes $0.28 for every $1 it owns (low), lower than 62% of Healthcare companies in United States.
Dividend yield
NonePuma Biotechnology, Inc. does not currently pay a dividend.
Revenue growth
-1%Revenue fell 1% in the year to Dec 2025, and grew 0% a year on average over 3 years.
Profit growth
+3%Net profit rose 3% in the year to Dec 2025, and grew 2396% a year on average over 3 years.
Profit margin
13.6%Puma Biotechnology, Inc. keeps $14 of every $100 of revenue as net profit.
Cash quality
1.3×Cash from Puma Biotechnology, Inc.'s business was 1.3× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
5.6×Puma Biotechnology, Inc.'s operating profit covered its interest costs 5.6 times in the year to Dec 2025.
Cash vs debt
Net cashPuma Biotechnology, Inc. held $69 M more cash than debt (net cash) at Dec 2025.
Questions
What is Puma Biotechnology, Inc.'s P/E ratio?
Investors pay $22.1 for every $1 of Puma Biotechnology, Inc.'s yearly profit, lower than 59% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Puma Biotechnology, Inc.: $581 M ÷ $139 M (30 Jun 2026) = 4.2.
What is Puma Biotechnology, Inc.'s return on equity?
Puma Biotechnology, Inc. earned 22.0% on its shareholders' money over the last year, higher than 91% of Healthcare companies in United States.
How much does Puma Biotechnology, Inc. owe compared with what it owns?
Puma Biotechnology, Inc. owes $0.28 for every $1 it owns (low), lower than 62% of Healthcare companies in United States.
Does Puma Biotechnology, Inc. pay a dividend?
No. Puma Biotechnology, Inc. does not currently pay a dividend.
Is Puma Biotechnology, Inc.'s revenue growing?
Revenue fell 1% in the year to Dec 2025, and grew 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.